Physician profile
Xiaorong Dai
NPI 1407901028
$879.56
in general payments reported to CMS, 2019-2025
15 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $55.38 · 2021: $23.04 · 2022: $49.05 · 2023: $239 · 2024: $176 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $137.28 | 2024-2025 | |
| Astellas Pharma US INC | $109.76 | 2023-2025 | Veozah |
| Pfizer INC. | $87.84 | 2021-2023 | |
| Abbvie INC. | $75.86 | 2019-2020 | |
| Exeltis, USA INC. | $71.27 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.28 | 2019-2023 | |
| Hologic Sales and Service, LLC | $55.30 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Organon LLC | $46.78 | 2024 | |
| Aspira Women'S Health INC | $45.44 | 2019-2020 | |
| Channel Medsystems, INC. | $37.93 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $37.62 | 2023 | Seglentis |
| Millicent US INC | $36.06 | 2024-2025 | Femring, Intrarosa |
| Dysis Medical, INC. | $34.17 | 2023 | Dysis View, Dysis V3 Digital Coploscope, Dysis Ultra 2.0 |
| Amag Pharmaceuticals, INC. | $31.83 | 2019 | |
| Coopersurgical, INC. | $13.14 | 2023 | Summit Doppler |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaorong Dai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.